Taiwan · Delayed Price · Currency is TWD Pharmasaga Statistics
Total Valuation
Pharmasaga has a market cap or net worth of TWD 8.46 billion. The enterprise value is 7.97 billion.
| Market Cap | 8.46B |
| Enterprise Value | 7.97B |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmasaga has 53.54 million shares outstanding. The number of shares has increased by 21.93% in one year.
| Current Share Class | 53.54M |
| Shares Outstanding | 53.54M |
| Shares Change (YoY) | +21.93% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 21.94% |
| Owned by Institutions (%) | 7.26% |
| Float | 39.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 14.50 |
| P/TBV Ratio | 16.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 41.51, with a Debt / Equity ratio of 0.01.
| Current Ratio | 41.51 |
| Quick Ratio | 39.50 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -385.35 |
Financial Efficiency
Return on equity (ROE) is -15.68% and return on invested capital (ROIC) is -11.23%.
| Return on Equity (ROE) | -15.68% |
| Return on Assets (ROA) | -11.03% |
| Return on Invested Capital (ROIC) | -11.23% |
| Return on Capital Employed (ROCE) | -18.94% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -6.43M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 204.31 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.19 |
| Average Volume (20 Days) | 370,102 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -111.37M |
| Pretax Income | -96.38M |
| Net Income | -96.38M |
| EBITDA | -103.69M |
| EBIT | -111.37M |
| Earnings Per Share (EPS) | -1.80 |
Balance Sheet
The company has 499.37 million in cash and 6.48 million in debt, with a net cash position of 492.90 million or 9.21 per share.
| Cash & Cash Equivalents | 499.37M |
| Total Debt | 6.48M |
| Net Cash | 492.90M |
| Net Cash Per Share | 9.21 |
| Equity (Book Value) | 583.17M |
| Book Value Per Share | 10.89 |
| Working Capital | 513.73M |
Cash Flow
In the last 12 months, operating cash flow was -73.47 million and capital expenditures -2.27 million, giving a free cash flow of -75.73 million.
| Operating Cash Flow | -73.47M |
| Capital Expenditures | -2.27M |
| Depreciation & Amortization | 7.67M |
| Net Borrowing | -842,000 |
| Free Cash Flow | -75.73M |
| FCF Per Share | -1.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharmasaga does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.93% |
| Shareholder Yield | -21.93% |
| Earnings Yield | -1.14% |
| FCF Yield | -0.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |